Funder
This study was supported in part by grants of Shin-Nihon Foundation of Advanced Medical Treatment Research.
MEXT | Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. The New England journal of medicine 372, 1909–1919,
https://doi.org/10.1056/NEJMoa1414325
(2015).
2. Emura, T. et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. International journal of molecular medicine 13, 249–255 (2004).
3. Matsuoka, K. et al. Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks. Molecular cancer therapeutics 14, 1004–1013,
https://doi.org/10.1158/1535-7163.MCT-14-0236
(2015).
4. Tanaka, N. et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncology reports 32, 2319–2326,
https://doi.org/10.3892/or.2014.3487
(2014).
5. Lin, P. F., Zhao, S. Y. & Ruddle, F. H. Genomic cloning and preliminary characterization of the human thymidine kinase gene. Proceedings of the National Academy of Sciences of the United States of America 80, 6528–6532 (1983).
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献